RBR-4hm9bf尚未招募2 期
A phase 2b, randomized, double-blind, placebo controlled multi-center study evaluating antiviral effects, pharmacokinetics, safety, and tolerability of GS-5806 in hematopoietic cell transplant (HCT) recipients with respiratory syncytial virus (RSV) infection of the upper respiratory tract
Fundação Doutor Amaral Carvalho0 个研究点开始时间: 2016年3月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 75Y（—）
入选标准
- •Received an autologous or allogeneic hematopoietic cell transplantation (HCT) using any conditioning regimen; Documented to be RSV-positive (respiratory syncytial virus) as determined by local testing for example, PCR (polymerase chain reaction), DFA (direct fluorescent antibody), RVP (respiratory virus pannel) assay, or culture using an upper respiratory tract sample collected 6 days or less prior to Day 1; New onset of at least 1 of the following respiratory symptoms for 7 days or less prior to Day 1: nasal congestion, runny nose, cough, or sore throat, or worsening of one of these chronic respiratory symptoms 7 days or less prior to Day 1; No evidence of new abnormalities consistent with LRTI on a chest X-ray relative to the most recent chest X-ray, as determined by the local radiologist. If a chest X-ray is not available or was not obtained during standard care 48 hours or less prior to Screening, a chest X-ray must be obtained for Screening; O2 saturation equal or higher than 92% on room air; An informed consent document signed and dated by the subject or a legal guardian of the subject and the investigator or his or her designee; A negative urine or serum pregnancy test is required for female subjects, unless surgically sterile or greater than two years post-menopausal; Male and female subjects of childbearing potential must agree to contraceptive requirements as described in Appendix 5; Willingness to complete necessary study procedures and have available a working telephone or email.
排除标准
- •Related to concomitant or previous medication use: Use of non-marketed according to region investigational agents within 30 days, OR use of any monoclonal anti-RSV antibodies within 4 months or 5 half-lives of Screening, whicheveris longer, OR use of any investigational RSV vaccines after HCT; Use of a strong cytochrome P450 enzyme inducer including but not limited to rifampin, St. John’s Wort, carbamazepine, and phenytoin, within 2 weeks prior to the first dose of IMP; Related to medical history: Admitted to the hospital primarily for a lower respiratory tract disease of any cause as determined by the investigator; Pregnant, reastfeeding, or lactating females; Unable to tolerate nasal sampling required for this study, as determined by the investigator; Known history of HIV and or AIDS with a CD4 count <200 cells/microL within the last month; History of drug and/or alcohol abuse that, in the opinion of the investigator, may prevent adherence to study activities; Related to medical condition at Screening: A relapse, including molecular relapse, of the underlying disease for which they received a transplant at Screening; Documented to be positive for other respiratory viruses limited to influenza, parainfluenza, human rhinovirus, adenovirus, or human metapneumovirus within 7 days prior to the Screening visit, as determined by local testing; Clinically significant bacteremia or fungemia within 7 days prior to Screening that has not been adequately treated, as determined by the investigator; Clinically significant bacterial, fungal, or viral pneumonia within 2 weeks prior to Screening that has not been adequately treated, as determined by the investigator; Excessive nausea/vomiting at Screening, as determined by the investigator, or an inability to swallow pills that precludes oral administration of the IMP; Any condition which, in the opinion of the investigator, would prevent full participation in this trial or would interfere with the evaluation of the trial endpoints; Related to allergies: Known hypersensitivity or allergy to the IMP, its metabolites, or formulation excipients like microcrystalline cellulose, mannitol, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol and talc; Allergy to sulfa drugs; Related to laboratory results: Creatinine clearance lesser than 30 mL/min, calculated using the Cockcroft-Gault method; AST/ALT higher than 3x ULN; Total bilirubin higher than 3x ULN.
研究者
相似试验
招募中
2 期
A study of oral GRC 17536 in treatment of painful diabetic peripheral neuropathy to find an effective dose of GRC 17536 to reduce the level of paiCTRI/2021/08/035410Glenmark Specialty SA
进行中（未招募）
不适用
A phase II, double-blind, randomized, placebo controlled study to compare the immunogenicity, reactogenicity and safety of two different formulations of GlaxoSmithKline (GSK) Biologicals’ live attennuated human rotavirus (HRV) vaccine given as a two-dose primary vaccination in healthy infants previously uninfected with HRV - Rota-048Immunization of healthy infants against HRV disease/illness.EUCTR2005-000449-12-FIGlaxoSmithKline250
进行中（未招募）
不适用
Efficacy and safety study of 4 doses of QGE031 in patients 18-50 years of age with peanut allergyEUCTR2011-000631-92-GBovartis Pharma Services AG110
进行中（未招募）
不适用
A phase II, randomized, double-blind, placebo controlled trial of Sorafenib as adjuvant treatment for hepatocellular carcinoma after TACE-based treatments. - ONC-2009-002hepatocellular carcinomaEUCTR2010-023411-33-ITISTITUTO CLINICO HUMANITAS
进行中（未招募）
不适用
Efficacy and safety study of 4 doses of QGE031 in patients 18-50 years of age with peanut allergyEUCTR2011-000631-92-NLovartis Pharma AG110